Loading
A phase 2/3 trial of Trastuzumab brengitecan, Pertuzumab, Docetaxel in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer is a phase 2/3 interventional study registered as NCT06891833 by Sichuan Baili Pharmaceutical Co., Ltd., with 985 participants planned, started 2025-06-05 and due to reach its primary completion in 2028-12. Interventions recorded: BL-M07D1, Pertuzumab, docetaxel, carboplatin, trastuzumab. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Trastuzumab.
Shares Trastuzumab brengitecan, Pertuzumab, SystImmune / Sichuan Biokin, Docetaxel.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, Docetaxel.
Shares Trastuzumab brengitecan, Early HER2-positive breast cancer, SystImmune / Sichuan Biokin, HER2-positive breast cancer.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Early HER2-positive breast cancer, Pertuzumab, HER2-positive breast cancer, Monoclonal antibodies.
Shares Early HER2-positive breast cancer, Pertuzumab, Trastuzumab, HER2-positive breast cancer.